New XOMA Antibodies Unveiled at The Society for Immunotherapy of Cancer 31st Annual Meeting
November 08 2016 - 09:00AM
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and
development of therapeutic antibodies, today unveiled its
interleukin-2 (IL-2) monoclonal antibody program, a series of novel
agents from its scientific discovery research unit, and announced
the advancement of its parathyroid hormone receptor 1 (PTH1R)
antibody antagonists program. These novel monoclonal
antibodies are further examples of the capability of XOMA’s
antibody platform and its expertise in the identification of novel
oncology and oncology-related candidates with potential to
positively affect outcomes in cancer patients.
“With our strategic focus on advancing our
endocrine programs, we continue to seek ways to support and fund
these efforts through discovery and licensing of our non-endocrine
assets. For our oncology antibodies, we seek partners who
have a deep commitment to and expertise in oncology drug
development. An example of this is the TGF-beta antibody
program that we licensed to Novartis last year, which we believe is
advancing rapidly to initiation of clinical studies in the near
future,” said John Varian, Chief Executive Officer of XOMA.
“We have unique expertise in creating new antibodies to treat a
variety of cancers and the side effects associated with currently
marketed therapies. As with our TGF-beta antibody program, we
plan to out-license our IL-2 and PTH1R antibody programs to
organizations that can rapidly advance them into clinical
development.”
IL-2 Monoclonal Antibodies
ProgramImmune checkpoint inhibitors are transforming
cancer treatment and revitalizing interest in immunotherapies.
While efficacy has been observed in patients with advanced
metastatic disease treated with checkpoint inhibitors, not all
patients respond, and most responses are incomplete.
Preclinical studies suggest that combining additional
modalities with checkpoint inhibitors will provide opportunities to
improve patient outcomes.
“IL-2 has long been recognized as an effective
therapy for metastatic melanoma and renal cell carcinoma, but it
has serious dose-limiting toxicities that prevent broad clinical
use. We generated novel antibodies that, when given with
IL-2, are intended to steer IL-2 to enhance its positive impact
with less toxicity, potentially improving the therapeutic index
over standard IL-2 therapy,” commented Paul Rubin, M.D., Senior
Vice President, Research and Development, and Chief Medical Officer
of XOMA.
A poster highlighting preclinical data from the
IL-2 monoclonal antibodies program will be presented at The Society
for Immunotherapy of Cancer (SITC) 31st Annual Meeting &
Associated Programs. The meeting will take place November
9-13 at the Gaylord National Hotel and Convention Center in
National Harbor, Maryland.
Poster Presentation
DetailsTitle: Novel IL-2/mAb complexes
mediate potent anti-tumor immunity which is augmented with
anti-PD-1 mAb therapyPoster Topic: Combinations:
Immunotherapy/Immunotherapy Abstract
Number: 454Poster Session Date: Saturday,
November 12, 2016 Poster Session Time: 11:45
a.m. – 1:00 p.m. ET
The abstract can be viewed on the SITC website
at www.sitcancer.org/2016.
PTH1R Monoclonal Antibodies
ProgramXOMA has developed several unique functional
antibody antagonists targeting PTH1R, a G-protein-coupled receptor
involved in the regulation of calcium metabolism. These
antibodies have shown promising efficacy in in vivo studies and
could potentially address high unmet medical needs, including
primary hyperparathyroidism (PHPT) and humoral hypercalcemia of
malignancy (HHM). The Company plans to present preclinical
data at a scientific conference later this year.
“Our PTH1R program began as an endocrine
program, but its mechanism-of-action is potentially also beneficial
to patients suffering from HHM. HHM is present in many
advanced cancers and is caused by high serum calcium due to
increased levels of the PTH1R ligand PTH-related peptide (PTHrP).
Since current HHM treatments often fall short and many cancer
patients die from ‘metabolic death’, XOMA’s PTH1R antibodies could
be very beneficial for the treatment of HHM,” stated Patrick
Scannon, M.D., Ph.D., Executive Vice President and Chief Scientific
Officer of XOMA.
About XOMA CorporationXOMA
Corporation is a leader in the discovery and development of
therapeutic antibodies. The Company's innovative product candidates
result from its expertise in developing ground-breaking monoclonal
antibodies, including allosteric antibodies, which have created new
opportunities to potentially treat a wide range of human diseases.
XOMA's scientific research has produced a portfolio of endocrine
assets, each of which has the opportunity to address multiple
indications. The Company's lead product candidate, XOMA 358,
is an allosteric monoclonal antibody that reduces insulin receptor
activity, which could have a major impact on the treatment of
hyperinsulinism. The Company is conducting Phase 2
development activities for XOMA 358 in patients with congenital
hyperinsulinism and in patients with hypoglycemia after bariatric
surgery. For more information, visit www.xoma.com.
Forward-Looking
StatementsCertain statements contained in this press
release are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, including statements regarding:
the future progress of XOMA’s discovery and development programs,
the medical need and market demand for XOMA’s immuno-oncology
assets, our belief that the TGF-beta program licensed to Novartis
last year is advancing rapidly to initiation of Phase 1 clinical
studies, the potential for licensing our immuno-oncology assets,
the possibility that combining additional modalities with
checkpoint inhibitors will provide opportunities to improve patient
outcomes, our belief that IL-2 directed antibodies complexed with
IL-2 offer advantages over standard IL-2 therapy, our belief that
our PTH1R antibodies could serve indications of high unmet medical
need such as HHM and PHPT, and statements that otherwise relate to
future periods. These statements are based on assumptions that may
not prove accurate, and actual results could differ materially from
those anticipated due to certain risks inherent in the
biotechnology industry and for companies engaged in the development
of new products in a regulated market. Potential risks to XOMA
meeting these expectations are described in more detail in XOMA's
most recent filing on Form 10-K and in other SEC filings. Consider
such risks carefully when considering XOMA's prospects. Any
forward-looking statement in this press release represents XOMA's
views only as of the date of this press release and should not be
relied upon as representing its views as of any subsequent date.
XOMA disclaims any obligation to update any forward-looking
statement, except as required by applicable law.
CONTACT: XOMA Corporation
Company and investor contact:
Ashleigh Barreto
510-204-7482
barreto@xoma.com
Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com
Media contact:
Julie Normart
W2O Group
415-946-1087
jnormart@w2ogroup.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Feb 2024 to Mar 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2023 to Mar 2024